Depression affects up to 25% of cancer patients — four to five times the general population rate — yet it remains chronically underrecognized and undertreated in oncology settings. A new retrospective analysis of over 265,000 Medicare beneficiaries, presented at the ASTRO Annual Meeting, found that patients with pre-existing major depressive disorder were significantly more likely to die of their cancer within 1 year (29% vs. 21%) and 5 years (43% vs. 35%) compared to those without depression.

The good news: early intervention makes a real difference. Patients who received psychotherapy within 4 weeks of their cancer diagnosis had a 21% lower risk of cancer-specific mortality compared to those who didn't. Notably, psychotherapy outperformed antidepressant medications, which showed no significant mortality benefit in the overall cohort. The benefit of psychotherapy also diminished the longer patients waited to receive it.

By the Numbers:

• 22% of the 265,639-person cohort had a major depressive disorder diagnosis
• 21% reduction in cancer-specific mortality risk with psychotherapy within 4 weeks of diagnosis
• Less than 5% of patients received psychotherapy within 12 weeks of cancer diagnosis
• 32.5% received antidepressant medication within 4 weeks — but with no significant overall mortality benefit

Why it matters: With well-established treatments available and a clear survival benefit on the table, the real barrier is access and recognition. Researchers are calling for routine mental health screening at the first oncology visit — a simple step that could meaningfully improve cancer outcomes.